Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer
Future Oncology · 2023-07 · 19 (22) · 1523-1534
DOI: 10.2217/fon-2022-1146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, online erschienen am 18.05.2023. Verfasst von Ryan T Hughes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Head and Neck Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Association of University Radiologists, National Cancer Institute.
Abstract (Originalsprache)
Effective treatments for advanced/recurrent head and neck squamous-cell carcinoma are limited. For cases not curable by conventional local therapies, the immune checkpoint inhibitor pembrolizumab shows modest response rates. Quad-shot, a hypofractionated palliative radiotherapy regimen (14.8 Gy in four twice-daily fractions), can provide symptomatic relief, contributes to local control and may potentiate the effects of immune checkpoint inhibitors. In this study, 15 patients with advanced/recurrent head and neck squamous-cell carcinoma will be treated with pembrolizumab combined with up to three administrations of quad-shot before cycles four, eight and 13. Outcomes include disease response, survival and treatment toxicity. Correlative multiomics analysis of blood and saliva will identify molecular biomarkers of response to immune checkpoint inhibitor and the immune-related impact of quad-shot. Clinical trial registration: This study (WFBCCC 60320) is registered on NCT04454489 (ClinicalTrials.gov). Advanced and recurrent head and neck cancers are difficult to treat. Most patients receive systemic therapies, such as chemotherapy or immunotherapy, with modest rates of cancer control. We aim to test the effectiveness of an immunotherapy drug called pembrolizumab in combination with a type of low-dose radiation therapy called quad-shot. Patients will receive pembrolizumab every 3 weeks and will be treated with one to three low-dose radiation therapy courses targeted at their cancer in the head and neck approximately every 12 weeks. We plan to measure how well the cancer responds to treatment, how long this response lasts, how long patients survive and treatment side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
- Department of Internal Medicine, Section of Hematology & Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
- Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
- Department of Biostatistics & Data Science, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
- Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
ORCID-Profile: Ryan T Hughes, Rediet R Gebeyehu, Thomas W Lycan, Ralph B D'Agostino, Pierre Triozzi, Cristina M Furdui, Mercedes Porosnicu
Förderung
- NCI NIH HHS
- Association of University Radiologists
- National Cancer Institute
Zitieren
APA
Hughes, R. T., Gebeyehu, R. R., Kalada, J. M., Lycan, T. W., Frizzell, B. A., Kinney, R. D., D'Agostino, R. B., Bunch, P. M., Triozzi, P., Zhang, W., Furdui, C. M., & Porosnicu, M. (2023). Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer. Future Oncology, 19(22), 1523-1534. https://doi.org/10.2217/fon-2022-1146
Vancouver
Hughes RT, Gebeyehu RR, Kalada JM, Lycan TW, Frizzell BA, Kinney RD, et al. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer. Future Oncology. 2023;19(22):1523-1534. doi:10.2217/fon-2022-1146
BibTeX
@article{Hughes2023,
author = {Hughes, Ryan T and Gebeyehu, Rediet R and Kalada, John Mason and Lycan, Thomas W and Frizzell, Bart A and Kinney, Rebecca D and D'Agostino, Ralph B and Bunch, Paul M and Triozzi, Pierre and Zhang, Wei and Furdui, Cristina M and Porosnicu, Mercedes},
title = {Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer},
journal = {Future Oncology},
year = {2023},
volume = {19},
number = {22},
pages = {1523--1534},
doi = {10.2217/fon-2022-1146}
}
EUVIMED